The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients
- PMID: 31784033
- DOI: 10.1016/j.atherosclerosis.2019.11.009
The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients
Keywords: Coronary artery disease; Familial hypercholesterolaemia; LDL-Cholesterol; PCSK9 inhibitors; Triple lipid-lowering therapy.
Comment on
-
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31. Atherosclerosis. 2019. PMID: 31591002 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
